Market Research Logo

Global Metabolic Disorders Therapeutics Market 2016-2020

Global Metabolic Disorders Therapeutics Market 2016-2020

About Metabolic Disorders

Metabolic disorders occur as a result of disruption of chemical processes and conversions occurring in the cells and fluids of the body. This is mainly because of defects in the enzyme; all process in the body are controlled by enzymes. Any disruption in the pathways involved in the development and metabolism of carbohydrates, proteins, fats, and nucleic acids, results in the development of metabolic disorders.

Technavio’s analysts forecast the global metabolic disorders therapeutics market to grow at a CAGR of 4.62% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global metabolic disorders therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of various metabolic disorders including diabetes, obesity, lysosomal storage diseases, and hypercholesterolemia.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Metabolic Disorders Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Novo Nordisk
  • Sanofi
  • Merck
  • AstraZeneca
  • Eli Lilly
Other prominent vendors
  • AbbVie
  • Actelion Pharmaceuticals
  • Adocia
  • Aegerion Pharmaceuticals
  • Akros Pharma
  • Alnylam Pharmaceuticals
  • Amarin
  • nAmgen
  • Amicus Therapeutics
  • Arbutus Biopharma
  • Arena Pharmaceuticals
  • Astellas Pharma
  • Atheronova
  • Aurobindo Pharma
  • Baxalta
  • Belrose Pharma
  • BHV Pharma
  • Biocon
  • Biodel
  • BioMarin
  • Bionaturis
  • Biosidus
  • Biospherics
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Catabasis Pharmaceuticals
  • Cerenis Therapeutics
  • Chipscreen Biosciences
  • Cipla
  • CJ HealthCare
  • CKD Bio
  • Concord Biotech
  • ConjuChem
  • CureDm
  • CymaBay Therapeutics
  • Daewoong
  • Daiichi Sankyo
  • Dance Biopharm
  • DiaMedica
  • Diamyd Therapeutics
  • Diasome Pharmaceuticals
  • DiaVacs
  • Dong-A ST
  • Eisai
  • Elcelyx Therapeutics
  • Esperion Therapeutics
  • Exsulin
  • F. Hoffmann-La Roche
  • Gan & Lee Pharmaceuticals
  • Generex Biotechnology
  • Genfit
  • GlaxoSmithKline
  • HanAll BioPharma
  • Hanmi Pharmaceutical Company
  • Hua Medicine
  • Iltoo Pharma
  • Intarcia Therapeutics
  • InteKrin Therapeutics
  • Intrexon
  • Ionis Pharmaceuticals
  • Islet Sciences
  • ISU Abxis
  • Janssen Pharmaceuticals
  • Japan Tobacco
  • JCR Pharmaceuticals
  • JW Pharmaceuticals
  • Kadmon Pharmaceuticals
  • Kamada
  • KinDex Pharmaceuticals
  • Kissei
  • Kotobuki
  • Kowa Company
  • Laboratoires SMB
  • Lexicon Pharmaceuticals
  • Ligand Pharmaceuticals
  • Living Cell Technologies
  • Livzon
  • LIXTE Biotechnology
  • Lupin
  • MacroGenics
  • Madrigal Pharmaceuticals
  • MannKind
  • MedImmune
  • Melior Pharmaceuticals
  • Merrion Pharmaceuticals
  • Merz Pharmaceuticals
  • Metabolic Solutions Development Company
  • Mitsubishi Tanabe Pharma
  • Mylan
  • Neothetics
  • Neuraltus Pharmaceuticals
  • NGM Biopharmaceuticals
  • NGM Biopharmaceuticals
  • Norgine BV
  • Novartis
  • NuSirt Biopharma
  • Oramed
  • Orexigen Therapeutics
  • Osiris Therapeutics
  • Peptron
  • Perle Biosciences
  • Pfizer
  • PhaseBio Pharmaceuticals
  • Poxel
  • Protalix Biotherapeutics
  • Raptor
  • Recordati
  • Regeneron Pharmaceuticals
  • Regeneron Pharmaceuticals
  • REGiMMUNE
  • Rhythm Pharmaceuticals
  • Saniona
  • Santaris Pharma
  • Santaris Pharma
  • Serometrix
  • Shionogi
  • Shire
  • Sigma-Tau
  • Sirona Biochem
  • Strongbridge Biopharma
  • SUN Pharma
  • Takeda
  • Teva
  • Thera technologies
  • Theracos
  • Toleranzia
  • Tolerion
  • Torrent Pharmaceuticals
  • Transition Therapeutics
  • UCB
  • Utrecht Holdings
  • VeroScience
  • Vivus
  • vTv Therapeutics
  • XBiotech
  • Xeris Pharmaceuticals
  • XOMA
  • Zafgen
  • Zydus Cadila
Market driver
  • Increase in academia-industry collaborations for drug development
  • For a full, detailed list, view our report
Market challenge
  • Low compliance and adherence rates
  • For a full, detailed list, view our report
Market trend
  • Increase in academia-industry collaborations for drug development
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Metabolic Disorders Therapeutics Market 2016-2020

Technavio recognizes the following companies as the key players in the global metabolic disorders therapeutics market: Novo Nordisk, Sanofi, Merck, AstraZeneca, and Eli Lilly.

Other Prominent Vendors in the market are: AbbVie, Actelion Pharmaceuticals, Adocia, Aegerion Pharmaceuticals, Akros Pharma, Alnylam Pharmaceuticals, Amarin, nAmgen, Amicus Therapeutics, Arbutus Biopharma, Arena Pharmaceuticals, Astellas Pharma, Atheronova, Aurobindo Pharma, Baxalta, Belrose Pharma, BHV Pharma, Biocon, Biodel, BioMarin, Bionaturis, Biosidus, Biospherics, Boehringer Ingelheim, Bristol-Myers Squibb, Catabasis Pharmaceuticals, Cerenis Therapeutics, Chipscreen Biosciences, Cipla, CJ HealthCare, CKD Bio, Concord Biotech, ConjuChem, CureDm, CymaBay Therapeutics, Daewoong, Daiichi Sankyo, Dance Biopharm, DiaMedica, Diamyd Therapeutics, Diasome Pharmaceuticals, DiaVacs, Dong-A ST, Eisai, Elcelyx Therapeutics, Esperion Therapeutics, Exsulin, F. Hoffmann-La Roche, Gan & Lee Pharmaceuticals, Generex Biotechnology, Genfit, GlaxoSmithKline, HanAll BioPharma, Hanmi Pharmaceutical Company, Hua Medicine, Iltoo Pharma, Intarcia Therapeutics, InteKrin Therapeutics, Intrexon, Ionis Pharmaceuticals, Islet Sciences, ISU Abxis, Janssen Pharmaceuticals, Japan Tobacco, JCR Pharmaceuticals, JW Pharmaceuticals, Kadmon Pharmaceuticals, Kamada, KinDex Pharmaceuticals, Kissei, Kotobuki, Kowa Company, Laboratoires SMB, Lexicon Pharmaceuticals, Ligand Pharmaceuticals, Living Cell Technologies, Livzon, LIXTE Biotechnology, Lupin, MacroGenics, Madrigal Pharmaceuticals, MannKind, MedImmune, Melior Pharmaceuticals, Merrion Pharmaceuticals, Merz Pharmaceuticals, Metabolic Solutions Development Company, Mitsubishi Tanabe Pharma, Mylan, Neothetics, Neuraltus Pharmaceuticals, NGM Biopharmaceuticals, NGM Biopharmaceuticals, Norgine BV, Novartis, NuSirt Biopharma, Oramed, Orexigen Therapeutics, Osiris Therapeutics, Peptron, Perle Biosciences, Pfizer, PhaseBio Pharmaceuticals, Poxel, Protalix Biotherapeutics, Raptor, Recordati, Regeneron Pharmaceuticals, Regeneron Pharmaceuticals, REGiMMUNE, Rhythm Pharmaceuticals, Saniona, Santaris Pharma, Santaris Pharma, Serometrix, Shionogi, Shire, Sigma-Tau, Sirona Biochem, Strongbridge Biopharma, SUN Pharma, Takeda, Teva, Thera technologies , Theracos, Toleranzia, Tolerion, Torrent Pharmaceuticals, Transition Therapeutics, UCB, Utrecht Holdings, VeroScience, Vivus, vTv Therapeutics, XBiotech, Xeris Pharmaceuticals, XOMA, Zafgen, and Zydus Cadila.

Commenting on the report, an analyst from Technavio’s team said: “Strategic collaborations and acquisitions will be a key trend for market growth. M&A are usually intended to enhance a company's product portfolio and increase the acquiring company's market penetration. Established pharmaceutical companies acquire late-stage products from small companies, where the product's efficacy has already been demonstrated, cutting down on initial R&D expenditure. Joint ventures between different companies enable the use of technical expertise from both companies for mutual benefits, allowing the use of regulatory and developmental experience gained by one company to support the pipeline candidates of the other. It also ensures the in-flow of adequate funds for R&D.”

According to the report, increase in academia-industry collaborations for drug development will be a key driver for market growth. The key players in the global diabetes therapeutics market are increasingly extending their support to academic institutions to facilitate the R&D of innovative products for the treatment of diabetes. Such collaborations enable the amalgamation of research expertise of educational institutions with the marketing intelligence of pharma companies, as well as provides funds for conducting trials.

Further, the report states that low compliance and adherence rates will be a challenge for the market. Despite the availability of various treatment options for metabolic disorders, there exist significant unmet medical needs because of the presence of adverse effects with the existing treatment options. Most of the therapies used for metabolic disorders should be continued on a long-term basis. Adverse effects lead to low compliance and adherence rates for these therapies. Also, the availability of alternative treatment options will discourage compliance.

Companies Mentioned

Novo Nordisk, Sanofi, Merck, AstraZeneca, and Eli Lilly. Other Prominent Vendors in the market are: AbbVie, Actelion Pharmaceuticals, Adocia, Aegerion Pharmaceuticals, Akros Pharma, Alnylam Pharmaceuticals, Amarin, nAmgen, Amicus Therapeutics, Arbutus Biopharma, Arena Pharmaceuticals, Astellas Pharma, Atheronova, Aurobindo Pharma, Baxalta, Belrose Pharma, BHV Pharma, Biocon, Biodel, BioMarin, Bionaturis, Biosidus, Biospherics, Boehringer Ingelheim, Bristol-Myers Squibb, Catabasis Pharmaceuticals, Cerenis Therapeutics, Chipscreen Biosciences, Cipla, CJ HealthCare, CKD Bio, Concord Biotech, ConjuChem, CureDm, CymaBay Therapeutics, Daewoong, Daiichi Sankyo, Dance Biopharm, DiaMedica, Diamyd Therapeutics, Diasome Pharmaceuticals, DiaVacs, Dong-A ST, Eisai, Elcelyx Therapeutics, Esperion Therapeutics, Exsulin, F. Hoffmann-La Roche, Gan & Lee Pharmaceuticals, Generex Biotechnology, Genfit, GlaxoSmithKline, HanAll BioPharma, Hanmi Pharmaceutical Company, Hua Medicine, Iltoo Pharma, Intarcia Therapeutics, InteKrin Therapeutics, Intrexon, Ionis Pharmaceuticals, Islet Sciences, ISU Abxis, Janssen Pharmaceuticals, Japan Tobacco, JCR Pharmaceuticals, JW Pharmaceuticals, Kadmon Pharmaceuticals, Kamada, KinDex Pharmaceuticals, Kissei, Kotobuki, Kowa Company, Laboratoires SMB, Lexicon Pharmaceuticals, Ligand Pharmaceuticals, Living Cell Technologies, Livzon, LIXTE Biotechnology, Lupin, MacroGenics, Madrigal Pharmaceuticals, MannKind, MedImmune, Melior Pharmaceuticals, Merrion Pharmaceuticals, Merz Pharmaceuticals, Metabolic Solutions Development Company, Mitsubishi Tanabe Pharma, Mylan, Neothetics, Neuraltus Pharmaceuticals, NGM Biopharmaceuticals, NGM Biopharmaceuticals, Norgine BV, Novartis, NuSirt Biopharma, Oramed, Orexigen Therapeutics, Osiris Therapeutics, Peptron, Perle Biosciences, Pfizer, PhaseBio Pharmaceuticals, Poxel, Protalix Biotherapeutics, Raptor, Recordati, Regeneron Pharmaceuticals, Regeneron Pharmaceuticals, REGiMMUNE, Rhythm Pharmaceuticals, Saniona, Santaris Pharma, Santaris Pharma, Serometrix, Shionogi, Shire, Sigma-Tau, Sirona Biochem, Strongbridge Biopharma, SUN Pharma, Takeda, Teva, Thera technologies , Theracos, Toleranzia, Tolerion, Torrent Pharmaceuticals, Transition Therapeutics, UCB, Utrecht Holdings, VeroScience, Vivus, vTv Therapeutics, XBiotech, Xeris Pharmaceuticals, XOMA, Zafgen, and Zydus Cadila.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
      • Table Key buying criteria and customer segments for metabolic disorder drugsKey buying criteria for metabolic disorders drugs 2015
      • Table Impact of key customer segments on market 2015
  • Pipeline portfolio
    • Pipeline portfolio: Global diabetes drugs market
    • Pipeline portfolio: Global hyperphosphatemia drugs market
    • Pipeline portfolio: Global anti-obesity drugs market
  • Market landscape
    • Market overview
      • Table Global metabolic disorders therapeutic market snapshot: Developed and emerging markets 2015
    • Market size and forecast
      • Table Global metabolic disorders therapeutics market 2015-2020 ($ billions)
      • Table Opportunity analysis: Global metabolic disorders therapeutics market
      • Table Global metabolic disorders therapeutics market: Growth cycle analysis
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by type of disease
    • Table Global metabolic disorders therapeutics market by type of disease
    • Diabetes
    • Obesity
    • Hypercholesterolemia
    • Lysosomal storage diseases
      • Table Global metabolic disorders therapeutics market by type (2015-2020)
      • Table Global metabolic disorders therapeutics market n growth lifecycle analysis
  • Global diabetes drugs market
    • Market overview
      • Table Top selling diabetes drugs based on sales 2015 ($ billions)
      • Table Market share of global diabetes drugs in global pharmaceutical market 2015
      • Table Global diabetes drugs market 2015-2020 ($ billions)
    • Global type 1 diabetes market
      • Table Global type 1 diabetes market 2015-2020 ($ billions)
    • Global type 2 diabetes drugs market
      • Table Global type 2 diabetes drugs market 2015-2020 ($ billions)
    • Vendors in global diabetes drugs market
      • Table Market share analysis of vendors in global diabetes drugs market
      • Table Revenues from the sales of top five products in global diabetes drugs market 2013-2015 ($ billions)
  • Global hypercholesterol emia drugs market
    • Market overview
      • Table Revenues from the sales of top five products in hypercholesterolemia drugs market 2013-2015 ($ billions)
      • Table Market dynamics of hypercholesterolemia drugs
      • Table Percentage share of hypercholesterolemia drugs by drug class 2015
      • Table Global hypercholesterolemia drugs market 2015-2020 ($ billions)
    • Vendors in global hypercholesterolemia drugs market
      • Table Market share analysis of global hypercholesterolemia drugs market 2015
      • Table Products offered by major vendors in global hypercholesterolemia drugs market
  • Global lysosomal storage diseases market
    • Market overview
      • Table Global lysosomal storage diseases drugs market 2015-2020 ($ billions)
      • Table Key events in treatment of lysosomal storage diseases
    • Vendors in global lysosomal storage disorders drugs market
      • Table Products offered by major vendors in global lysosomal storage disorders drugs market
  • Global antiobesity drugs market
    • Market overview
      • Table Global anti-obesity drugs market 2015-2020 ($ millions)
    • Vendors in global anti-obesity drugs market
      • Table Products offered by major vendors in global anti-obesity drugs market
  • Geographical segmentation
    • Global metabolic disorders therapeutics market by geography 2015-2020
      • Table Global metabolic disorders therapeutics market by geography 2015-2020
      • Table Global metabolic disorder therapeutics market by geography 2015 and 2020
      • Table Global metabolic disorder therapeutics market by geography 2015-2020 ($ billions)
      • Table Global share of metabolic disorder therapeutics market by geography 2015
      • Table Global share of various metabolic disorder therapeutics market by geography based on disease type 2015
      • Table Global metabolic disorders therapeutics market by region: Market growth lifecycle analysis 2015
    • Metabolic disorders therapeutics market in Americas
      • Table Metabolic disorder therapeutics market in Americas 2015-2020 ($ billions)
    • Metabolic disorders therapeutics market in EMEA
      • Table Prevalence of obesity in various countries in Europe 2025
      • Table Metabolic disorders therapeutics market in EMEA 2015-2020 ($ billions)
    • Metabolic disorders therapeutics market in APAC
      • Table Metabolic disorder therapeutics market in APAC 2015-2020 ($ billions)
      • Table Prevalence of diabetes in selected countries in APAC 2007 and 2025
  • Market drivers
    • Patient assistance programs
      • Table Few metabolic disorder drugs with patient assistance programs
    • Special regulatory designations for rare diseases
    • Increase in academia-industry collaborations for drug development
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Low compliance and adherence rates
    • High cost of therapies
    • Complex storage conditions and distribution policies for insulin
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Focus on oral insulin therapies
      • Table Oral insulin pipeline portfolio
    • Strong and diversified pipeline portfolio
      • Table Some investigational molecules for metabolic disorders and their mechanisms
    • Strategic collaborations and acquisitions
  • Vendor landscape
    • Competitive scenario
      • Table Key vendors ranking 2015
      • Table Geographical presence of key vendors
      • Table Competitive scenario of global metabolic disorders therapeutics market vendors 2015-2020
    • Other prominent vendors
  • Key vendor analysis
    • Novo Nordisk
      • Table Novo Nordisk: Profile
      • Table Novo Nordisk: Strength analysis
      • Table Novo Nordisk: Growth strategy matrix
      • Table Novo Nordisk: Growth opportunity assessment
      • Table Novo Nordisk: Business segmentation by revenue 2015
      • Table Novo Nordisk: Key products in diabetes and obesity care
      • Table Novo Nordisk: YoY growth and revenue generated from net product sales of human insulins 2012-2015 ($ billions)
      • Table Novo Nordisk: YoY growth and revenue generated from net product sales of Levemir 2012-2015 ($ billions)
      • Table Novo Nordisk: YoY growth and revenue of NovoRapid/ NovoLog 2012-2015 ($ billions)
      • Table Novo Nordisk: YoY growth and revenue of NovoMix/NovoLog Mix 2012-2015 ($ billions)
      • Table Novo Nordisk: Revenue generated from net product sales of new-generation insulins 2013-2015 ($ millions)
      • Table Novo Nordisk: YoY growth and revenue of Victoza 2012-2015 ($ billions)
      • Table Novo Nordisk: YoY growth and revenue of Novonorm, Prandin, and Prandimet 2012-2014 ($ billions)
    • Sanofi
      • Table Sanofi: Business segmentation by revenue 2015
      • Table Sanofi: Profile
      • Table Sanofi: Strength analysis
      • Table Sanofi growth strategy matrix
      • Table Sanofi: Growth opportunity assessment
      • Table Key product offerings in diabetes market ($ billions)
      • Table Sanofi: YoY revenue and growth rate of Lantus 2012-2015 ($ billions)
      • Table Sanofi: YoY revenue and growth rate of Amaryl 2012-2015 ($ billions)
      • Table Sanofi: YoY revenue and growth rate of Apidra 2012-2015 ($ billions)
      • Table Sanofi: YoY revenue and growth rate of Insuman 2012-2015 ($ billions)
      • Table Sanofi: YoY revenue and growth rate of Lyxumia 2013-2015 ($ millions)
      • Table Sanofi: Revenues of lysosomal storage diseases drugs of Genzyme, 2015
    • Merck
      • Table Merck: Strength profile
      • Table Merck: Strength analysis
      • Table Merck: Growth strategy matrix
      • Table Merck: Opportunity assessment
      • Table Top selling diabetes drugs in 2015
      • Table Merck: Diabetes segmentation by revenue 2015
      • Table Merck: YoY growth and revenue of Janumet 2012-2015 ($ billions)
      • Table Merck: YoY growth and revenue of Januvia 2012-2015 ($ billions)
      • Table Merck: YoY revenue and growth rate of Zetia 2013-2015 ($ billions)
      • Table Merck: YoY revenue and growth rate of Vytorin 2013-2015 ($ billions)
      • Table Merck: YoY revenue and growth rate of Zocor 2013-2015 ($ millions)
    • AstraZeneca
      • Table AstraZeneca: Profile
      • Table AstraZeneca: Strength analysis
      • Table AstraZeneca: Growth strategy matrix
      • Table AstraZeneca: Opportunity assessment
      • Table Top selling diabetes drugs in 2015 ($ billions)
      • Table AstraZeneca: Byetta YoY growth and revenues 2012-2015 ($ billions)
      • Table Astrazeneca: Byetta YoY growth rate and revenues in the US ($ billions)
      • Table AstraZeneca: Bydureon YoY revenues and growth rate 2012-2015 ($ billions)
      • Table AstraZeneca: Onglyza YoY revenue and growth rate 2012-2015 ($ billions)
      • Table AstraZeneca: YoY revenue and growth rate of Crestor 2013-2015 ($ billions)
      • Table AstraZeneca: Geographical segmentation of Crestor 2015 by revenue
    • Eli Lilly
      • Table Eli Lilly: Profile
      • Table Eli Lilly: Strength analysis
      • Table Eli Lilly growth strategy matrix
      • Table Eli Lilly: Opportunity assessment
      • Table Top selling diabetic drugs 2015 ($ billions)
      • Table Eli Lilly: YoY revenue and growth rate of Humalog 2012-2015 ($ billions)
      • Table Eli Lilly: YoY revenue and growth rate of Humulin 2012-2015 ($ billions)
      • Table Eli Lilly: YoY revenue and growth rate of Tradjenta 2012-2015 ($ billions)
      • Table Eli Lilly: YoY revenue of Trylicity 2014-2015 ($ millions)
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report